ReviewLancet (London, England)2015
Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection.
Review in Lancet (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03302299 (URBAN ARCH), which is not on this map. Cited by 97 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
URBAN ARCH (3/5) Uganda Cohort TB Preventive Therapy for HIV-infected Alcohol Users in Uganda: an Evaluation of Safety Tolerability and Adherence
Who cites it
97 citing papers in PubMed, 7 syntheses or guidelines pooled it, 217 citations in OpenAlex.
- Effect of BCG vaccination on the progression of latent tuberculosis infection to active disease in contacts: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- A systematic review exploring the role of tuberculosis stigma on test and treatment uptake for tuberculosis infection.BMC public health · 2025Pooled it
- Diabetes mellitus and latent tuberculosis infection: an updated meta-analysis and systematic review.BMC infectious diseases · 2023Pooled it
- Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review.BMC public health · 2022Pooled it
- Interferon-gamma release assay levels and risk of progression to active tuberculosis: a systematic review and dose-response meta-regression analysis.BMC infectious diseases · 2021Pooled it
- Pooled it
- Mortality in children diagnosed with tuberculosis: a systematic review and meta-analysis.The Lancet. Infectious diseases · 2017Pooled it
- Trial
- Potential health impacts and costs of active case finding guided by Mycobacterium tuberculosis immunoreactivity survey results in Blantyre, Malawi: A mathematical modeling study.PLoS medicine · 2026Article
- Optimizing Latent Tuberculosis Treatment Strategies Among Immigrants From High-Burden Settings.medRxiv : the preprint server for health sciences · 2026Article
- Stigma among patients with TB infection in a low-TB-burden setting.IJTLD open · 2026Article
- Observational
- The health impact of identifying a person with tuberculosis through systematic screening.The Lancet. Infectious diseases · 2025Review
- Article
- Long-term impact of national tuberculosis program interventions on incidence and disparities by age and geography.BMC infectious diseases · 2025Article
- Latent Tuberculosis Infection in Inflammatory Rheumatic Diseases Before Biological and Synthetic DMARD Treatment: Results from Three Rheumatology Centers in Different Regions of Türkiye.Thoracic research and practice · 2025Article
- Utilizing artificial intelligence to predict and analyze socioeconomic, environmental, and healthcare factors driving tuberculosis globally.Scientific reports · 2025Article
- Evaluation of Diagnostic Performance of Three Commercial Interferon-Gamma Release Assays forDiagnostics (Basel, Switzerland) · 2024Article
- Community-Wide Active Case Finding for Tuberculosis: Time to Use the Evidence We Have.Tropical medicine and infectious disease · 2024Review
- Three months of weekly rifapentine plus isoniazid for TB prevention among people with HIV.IJTLD open · 2024Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 6 institutions in 6 countries.
Funding
Abstract
The billions of people with latent tuberculosis infection serve as the seedbeds for future cases of active tuberculosis. Virtually all episodes of tuberculosis disease are preceded by a period of asymptomatic Mycobacterium tuberculosis infection; therefore, identifying infected individuals most likely to progress to disease and treating such subclinical infections to prevent future disease provides a crucial opportunity to interrupt tuberculosis transmission and reduce the global burden of tuberculosis disease. Programmes focusing on single strategies rather than comprehensive programmes that deliver an integrated arsenal for tuberculosis control might continue to struggle. Tuberculosis preventive therapy is a poorly used method that is essential for controlling the reservoirs of disease that drive the epidemic. Comprehensive control strategies that combine preventive therapy for the most high-risk populations and communities with improved case-finding and treatment, control of transmission, and health systems strengthening could ultimately lead to worldwide tuberculosis elimination. In this Series paper we outline challenges to implementation of preventive therapy and provide pragmatic suggestions for overcoming them. We further advocate for tuberculosis preventive therapy as the core of a renewed worldwide focus to implement a comprehensive epidemic control strategy that would reduce new tuberculosis cases to elimination targets. This strategy would be underpinned by accelerated research to further understand the biology of subclinical tuberculosis infections, develop novel diagnostics and drug regimens specifically for subclinical tuberculosis infection, strengthen health systems and community engagement, and enhance sustainable large scale implementation of preventive therapy programmes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.